0.82  -0.32 (-28.07%)		04-21 16:00
Open: 0.9797 High: 1.01 Volume: 11,833,135		Pre. Close: 1.14 Low: 0.7702 Market Cap: 0(M)

Short term
Mid term
Targets	6-month :	1.35	1-year :	1.77
Resists	First :	1.16	Second :	1.51
Pivot price	1.06
Supports	First :	0.58	Second :	0.48
MAs	MA(5) :	0.83	MA(20) :	0.99
	MA(100) :	2.02	MA(250) :	23.11
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	33	D(3) :	27
RSI	RSI(14): 44.9
52-week	High :	52.4	Low :	0.58

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ CMND ] has closed above bottom band by 22.8%. Bollinger Bands are 71.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 90 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	1.01 - 1.02	1.02 - 1.02
Low:	0.76 - 0.76	0.76 - 0.77
Close:	0.81 - 0.82	0.82 - 0.83

Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. It develops treatments for alcohol use disorders, including binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.

Tue, 21 Apr 2026
Clearmind shares surge as CMND-100 achieves primary endpoint in clinical trial - MSN

Mon, 20 Apr 2026
[6-K] Clearmind Medicine Inc. Current Report (Foreign Issuer) | CMND SEC Filing - Form 6-K - Stock Titan

Mon, 20 Apr 2026
Clearmind Medicine (CMND) Stock Surges 100% After Drug Trial Hit Safety Goals - MEXC

Mon, 20 Apr 2026
CMND Stock Jumps As Psychedelic Tailwinds Lift Clearmind - StocksToTrade

Mon, 20 Apr 2026
Clearmind Medicine jumps 64.7% after CMND-100 hits key safety endpoint in early AUD study - Quiver Quantitative

Mon, 20 Apr 2026
Why Is Clearmind Stock Rising Monday? - Clearmind Medicine (NASDAQ:CMND) - Benzinga

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	2 (M)
Shares Float	2 (M)
Held by Insiders	4.4 (%)
Held by Institutions	0.4 (%)
Shares Short	47 (K)
Shares Short P.Month	103 (K)

EPS	-24.13
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	5.48
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-55.3 %
Return on Equity (ttm)	-119.8 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-3.28
Qtrly Earnings Growth	0 %
Operating Cash Flow	-6 (M)
Levered Free Cash Flow	-5 (M)

PE Ratio	-0.04
PEG Ratio	0
Price to Book value	0.14
Price to Sales	0
Price to Cash Flow	-0.36

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.